Skip to main content

CORRECTION article

Front. Oncol., 29 February 2024
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Corrigendum: Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer

  • 1Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany
  • 2Medical Research Center, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany
  • 3Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany

A Corrigendum on:
Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer.

By Bai L, Pfeifer T, Gross W, De La Torre C, Zhao S, Liu L, Schaefer M and Herr I (2021) Front. Oncol. 11:738801. doi: 10.3389/fonc.2021.738801

Error in Figure 3

In the original article, there was a duplicated, representative image in Figure 3 as published. The representative image of “AsPC-1/CO/12h” was unintentionally swapped. The revised and correct Figure appears below.

Figure 3
www.frontiersin.org

Figure 3 TTField-mediated inhibition of migration is stronger upon combination with hyperthermia. AsPC-1, BxPC-3 and Bx-GEM cells were seeded at a density of 4,000 cells/well in 96-well plates and grown to 90% confluency overnight. The cell layer was scratched with the tip of a 100-μL pipet, followed by treatment of the cells with TTFields at 38.5°C for 24 h. The controls (CO) were incubated at 38.5°C without exposure to TTFields. The closure of the wounded region was evaluated by microscopy at 0, 12 and 24 h after scratching. The gap width was measured using ImageJ. Representative images are shown on the left, and the means are shown in bar graphs on the right. The data are presented as the means ± SD. *P < 0.05, **P < 0.01.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: pancreatic ductal adenocarcinoma, hyperthermia, tumor treating fields, alternative therapies, bioinformatics and computational biology

Citation: Bai L, Pfeifer T, Gross W, De La Torre C, Zhao S, Liu L, Schaefer M and Herr I (2024) Corrigendum: Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer. Front. Oncol. 14:1343421. doi: 10.3389/fonc.2024.1343421

Received: 23 November 2023; Accepted: 03 January 2024;
Published: 29 February 2024.

Edited and Reviewed by:

Liang Qiao, Westmead Institute for Medical Research, Australia

Copyright © 2024 Bai, Pfeifer, Gross, De La Torre, Zhao, Liu, Schaefer and Herr. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ingrid Herr, i.herr@uni-heidelberg.de

Present address: Liping Bai, Department of Gastrointestinal Surgery, The Affiliated Zhongshan Hospital, and Institute of Gastrointestinal Oncology, School of Medicine, Xiamen University, Xiamen, China

‡These authors share last authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.